64037-07-6

Usage

Uses

Used in Pharmaceutical Research:
5-BROMOBENZO[D]OXAZOL-2-AMINE is used as a building block for the synthesis of various biologically active molecules, contributing to drug discovery and development. Its unique structure and potential pharmacological properties make it a promising candidate for creating new therapeutic agents.
Used as a Chemical Intermediate:
In the chemical industry, 5-BROMOBENZO[D]OXAZOL-2-AMINE serves as an intermediate in the production of organic compounds. Its versatility allows for its use in the synthesis of a wide range of chemical products, enhancing its value in industrial applications.
While the provided materials do not specify different applications across various industries, the general uses outlined above encompass the primary roles of 5-BROMOBENZO[D]OXAZOL-2-AMINE in both pharmaceutical and chemical industries. Its potential for further applications in medicine and industry is vast, given its chemical properties and reactivity.

InChI:InChI=1/C7H5BrN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)

Upstream product

• 40925-68-6 2-amino-4-bromo-phenol 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 
• 1404480-03-0 C₇H₇BrN₂OS 
• 506-68-3 bromocyane 

Downstream Products

• 1224844-66-9 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine 
• 1404480-15-4 2-amino-benzooxazole-5-boronic acid hydrochloride 
• 1126637-54-4 5-phenylbenzo[d]oxazol-2-amine 
• 64037-13-4 5-iodo-1,3-benzoxazol-2-amine 
• 4570-41-6 1,3-benzoxazol-2-amine 
• 1224844-65-8 2-aminobenzo[d]oxazol-5-ylboronic acid 
• 1224844-38-5 INK128 
• 1268454-23-4 (6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone 
• 1415992-11-8 tert-butyl 4-[2-(4-carbamoyl-3-fluorophenyl)benzo[d]oxazol-5-yl]piperidine-1-carboxylate 
• 5459-02-9 5-7-Dibromo-3H-benzooxazol-2-one 
• 52112-67-1 5.7-Dibrom-2-amino-benzoxazol 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB

N-(5-Chlorobenzo[d]oxazol-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamideox-amide has been identified as a potent inhibitor of Mtb H37Rv, with a minimum inhibitory concentration (MIC) of 0.42 μM. In this study, a series of substituted 2-acylamide-1,3-zole analogues were designed and synthesized, and their anti-Mtb activities were analyzed. In total, 17 compounds were found to be potent anti-Mtb agents, especially against the MDR- and XDR-MTB strains, with MIC values 10 μM. These analogues can inhibit both drug-sensitive and drug-resistant Mtb. Four representative compounds were selected for further profiling, and the results indicate that compound 18 is acceptably safe and has favorable pharmacokinetic (PK) properties. In addition, this compound displays potent activity against Gram-positive bacteria, with MIC values in the range of 1.48–11.86 μM. The data obtained herein suggest that promising anti-Mtb candidates may be developed via structural modification, and that further research is needed to explore other compounds.

5-aryl substituted 2-aminobenzoxazole derivative and preparation method and application thereof

The invention discloses a 5-aryl substituted 2-aminobenzoxazole derivative and a preparation method and application thereof, and belongs to the technical field of pesticides, the 5-aryl substituted 2-aminobenzoxazole derivative is characterized in that th

5 - Pyridyl -2 - amino - benzo [d] oxazole derivative and its preparation and use (by machine translation)

The present invention discloses the general formula (I) indicated by the 5 - pyridyl - 2 - amino - benzo [d] oxazole derivative or its pharmaceutically acceptable salt, its preparation method, pharmaceutical composition and use: According to the compounds of this invention can be used for preparing the treatment of cervical cancer, breast cancer, stomach cancer, liver cancer, renal carcinomas of the drug. (by machine translation)

Substituted benzo - 1, 3 - [...] compound, its preparation and use

The invention relates to a substituted benzo-1, 3-miscellaneous azole compound shown in the general formula I, and further relates to a preparation method of the compound and application to the preparation of antituberculosis drugs. The compound provided by the invention has effect not only on mycobacterium tuberculosis sensitive strains, but also on resistant strains which have drug resistance to isoniazid, rifampicin, and other traditional frontline antituberculosis drugs, and is a novel antimycobacterium tuberculosis compound.

Enhanced treatment regimens using mTor inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

Electrochemical intramolecular c-h amination: Synthesis of benzoxazoles and benzothiazoles

A new method for metal-free intramolecular C-H amination has been developed. Electrochemical oxidation of 2-pyrimidyloxybenzenes and 2-pyrimidylthiobenzenes, which can be easily prepared from phenols and thiophenols, respectively, followed by the treatment of the resulting pyrimidinium ions with piperidine gives 2-aminobenzoxazoles and 2-aminobenzothiazoles, respectively.

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

KINASE INHIBITOR POLYMORPHS

Polymorphs, hydrates, and solvates of chemical compounds that modulate kinase activity, including mTOR activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mTOR activity, are described herein.